1
|
Kühl L, Schäfer AK, Kraft S, Aschmoneit N, Kontermann RE, Seifert O. eIg-based bispecific T-cell engagers targeting EGFR: Format matters. MAbs 2023; 15:2183540. [PMID: 36864566 PMCID: PMC9988351 DOI: 10.1080/19420862.2023.2183540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023] Open
Abstract
Bispecific antibodies are molecules with versatile modes of action and applications for therapy. They are commonly developed as T-cell engagers (TCE), which simultaneously target an antigen expressed by tumor cells and CD3 expressed by T-cells, thereby inducing T-cell-mediated target cell killing. There is growing evidence that the molecular composition and valency for the target antigen influence the activity of TCEs. Here, the eIg platform technology was used to generate a set of bispecific TCEs targeting epidermal growth factor receptors (EGFR) and CD3. These molecules either included or lacked an Fc region and exhibited one binding site for CD3 and either one or two binding sites for EGFR (1 + 1 or 2 + 1 formats) utilizing different molecular arrangements of the binding sites. In total, 11 different TCE formats were analyzed for binding to target cells and T cells, T cell-mediated killing of tumor cells, and for the activation of T cells (release of cytokines and proliferation of T-cells). Bivalent binding to EGFR strongly increased binding and T cell-mediated killing. However, the molecular composition and position of the CD3-binding arm also affected target cell killing, cytokine release, and T-cell proliferation. Our findings support that screening of a panel of formats is beneficial to identify the most potent bispecific TCE, and that format matters.
Collapse
Affiliation(s)
- Lennart Kühl
- Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany
| | - Annelie K Schäfer
- Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany
| | - Sebastian Kraft
- Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany
| | - Nadine Aschmoneit
- Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany
| | - Roland E Kontermann
- Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.,Stuttgart Research Center Systems Biology (SRCSB), University of Stuttgart, Stuttgart, Germany
| | - Oliver Seifert
- Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.,Stuttgart Research Center Systems Biology (SRCSB), University of Stuttgart, Stuttgart, Germany
| |
Collapse
|
2
|
Satta A, Grazia G, Caroli F, Frigerio B, Di Nicola M, Raspagliesi F, Mezzanzanica D, Zaffaroni N, Gianni AM, Anichini A, Figini M. A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. Front Immunol 2019; 10:2514. [PMID: 31708930 PMCID: PMC6823250 DOI: 10.3389/fimmu.2019.02514] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Accepted: 10/08/2019] [Indexed: 12/31/2022] Open
Abstract
T-cell-based immunotherapy strategies have profoundly improved the clinical management of several solid tumors and hematological malignancies. A recently developed and promising immunotherapy approach is to redirect polyclonal MHC-unrestricted T lymphocytes toward cancer cells by bispecific antibodies (bsAbs) that engage the CD3 complex and a tumor-associated antigen (TAA). The TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) is an attractive immunotherapy target, frequently expressed by neoplastic cells, that we decided to exploit as a TAA. We found that a TRAIL-R2xCD3 bsAb efficiently activates T cells and specifically redirect their cytotoxicity against cancer cells of different origins in vitro, thereby demonstrating its potential as a pan-carcinoma reagent. Moreover, to mimic in vivo conditions, we assessed its ability to retarget T-cell activity in an ex vivo model of ovarian cancer patients' ascitic fluids containing both effector and target cells—albeit with a suboptimal effector-to-target ratio—with remarkable results.
Collapse
Affiliation(s)
- Alessandro Satta
- Biomarkers Unit, Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Giulia Grazia
- Human Tumor Immunobiology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Francesco Caroli
- Chemical Clinical Analysis Area, Laboratory Medicine Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - Barbara Frigerio
- Biomarkers Unit, Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Massimo Di Nicola
- Immunotherapy and Innovative Anticancer Therapeutics Unit, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Francesco Raspagliesi
- Oncological Gynecology Unit, Surgery Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Delia Mezzanzanica
- Molecular Therapies Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Nadia Zaffaroni
- Molecular Pharmacology Unit, Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Alessandro Massimo Gianni
- Medical Oncology C Unit, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Andrea Anichini
- Human Tumor Immunobiology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Mariangela Figini
- Biomarkers Unit, Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
3
|
Cartellieri M, Arndt C, Feldmann A, von Bonin M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M. TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity. Oncoimmunology 2013; 2:e26770. [PMID: 24498554 PMCID: PMC3909541 DOI: 10.4161/onci.26770] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Accepted: 10/10/2013] [Indexed: 11/19/2022] Open
Abstract
We have recently described a novel modular targeting platform for T cell recruitment that not only efficiently replaces but also is superior to conventional T cell-engaging bispecific antibodies as it allows for the flexible targeting of several antigens and the delivery of co-stimulatory ligands to malignant lesions, thereby enhancing the antitumor potential of redirected T cells.
Collapse
Affiliation(s)
- Marc Cartellieri
- Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany
| | - Claudia Arndt
- Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany
| | - Anja Feldmann
- Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany ; Institute of Radiopharmaceutical Cancer Research; Helmholtz-Zentrum Dresden-Rossendorf; Dresden, Germany
| | - Malte von Bonin
- Medical Clinic and Polyclinic I; University Hospital 'Carl Gustav Carus'; TU Dresden; Dresden, Germany
| | - Eva-Maria Ewen
- Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany
| | - Stefanie Koristka
- Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany
| | - Irene Michalk
- Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany
| | - Slava Stamova
- Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany
| | - Nicole Berndt
- Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany
| | - Anne Gocht
- Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany
| | - Martin Bornhäuser
- Medical Clinic and Polyclinic I; University Hospital 'Carl Gustav Carus'; TU Dresden; Dresden, Germany
| | - Gerhard Ehninger
- Medical Clinic and Polyclinic I; University Hospital 'Carl Gustav Carus'; TU Dresden; Dresden, Germany
| | - Marc Schmitz
- Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany ; Center for Regenerative Therapies Dresden; TU Dresden; Dresden, Germany
| | - Michael Bachmann
- Institute of Immunology; Medical Faculty 'Carl Gustav Carus'; TU Dresden; Dresden, Germany ; Institute of Radiopharmaceutical Cancer Research; Helmholtz-Zentrum Dresden-Rossendorf; Dresden, Germany ; Center for Regenerative Therapies Dresden; TU Dresden; Dresden, Germany
| |
Collapse
|